A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate

被引:20
作者
Bronner, Felix [1 ]
Slepchenko, Boris M. [1 ]
Pennick, Michael [2 ]
Damment, Stephen J. P. [2 ]
机构
[1] Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA
[2] Shire Pharmaceut, Basingstoke, Hants, England
关键词
D O I
10.2165/00003088-200847080-00004
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Objective: Lanthanum carbonate (Fosrenol (R)) is a non-calcium phosphate binder that controls hyperphosphataemia without increasing calcium intake above guideline targets. The biological fate and bone load of lanthanum were modelled with the aid of a four-compartment kinetic model, analogous to that of calcium. Methods: The model used data from healthy subjects who received intravenous lanthanum chloride or oral lanthanum carbonate, and bone lanthanum concentration data collected from dialysis patients during three long-term trials (up to 5 years). Results: Infusion of lanthanum chloride or ingestion of lanthanum carbonate led to a rapid rise in plasma lanthanum concentrations, followed by an exponential decrease. Comparison of oral and intravenous exposure confirmed that lanthanum is very poorly absorbed. On a typical intake of lanthanum (3000 mg/day as lanthanum carbonate), the rate of absorption was calculated as 2.2 mu g/h, with a urinary excretion rate constant of 0.004-0.01 h(-1). The faecal content of endogenous lanthanum was estimated to be 8- to 20-fold greater than that of urine, compared with a ratio of only about 1 for calcium. The model predicts that upon multiple dosing, plasma lanthanum concentrations rise rapidly to a near plateau and then increase by about 3% per year. However, this small change is obscured by the variability of the study data, which show that a plateau is rapidly attained by 2 weeks and is thereafter maintained for at least 2 years. The initial deposition rate of lanthanum in bone was 1 mu g/g/year and, after 10 years of lanthanum carbonate treatment, the model predicts a 7-fold increase in total bone lanthanum (from 10 mg to 69 mg [from 1 mu g/g wet weight to 6.6 mu g/g wet weight]), with lanthanum cleared after cessation of treatment at 13% per year. The model indicates that lanthanum flow from bone surface to bone interior is much lower than that of calcium. Conclusion: Bone is the major reservoir for metals, but bone lanthanum concentrations are predicted to remain low after long-term treatment because of very poor intestinal absorption.
引用
收藏
页码:543 / 552
页数:10
相关论文
共 51 条
[1]
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy [J].
Altmann, P. ;
Barnett, M. E. ;
Finn, W. F. .
KIDNEY INTERNATIONAL, 2007, 71 (03) :252-259
[2]
QUANTITATION OF CALCIUM METABOLISM - THEORY [J].
AUBERT, JP ;
RICHELLE.LJ ;
BRONNER, F .
JOURNAL OF CLINICAL INVESTIGATION, 1963, 42 (06) :885-&
[3]
Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride [J].
Autissier, Valerie ;
Damment, Stephen J. P. ;
Henderson, Richard A. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (10) :2818-2827
[4]
Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate [J].
Behets, GJ ;
Verberckmoes, SC ;
Oste, L ;
Bervoets, AR ;
Salomé, M ;
Cox, AG ;
Denton, J ;
De Broe, ME ;
D'Haese, PC .
KIDNEY INTERNATIONAL, 2005, 67 (05) :1830-1836
[5]
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats [J].
Ben-Dov, Iddo Z. ;
Pappo, Orit ;
Sklair-Levy, Miri ;
Galitzer, Hillel ;
Ilan, Yaron ;
Naveh-Many, Tally ;
Silver, Justin .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (02) :362-368
[6]
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[7]
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[8]
Bronner F., 1997, Handbook of nutritionally essential mineral elements., P13
[9]
QUANTITATION OF CALCIUM METABOLISM IN POSTMENOPAUSAL OSTEOPOROSIS AND IN SCOLIOSIS [J].
BRONNER, F ;
COBB, JR ;
NICHOLAS, JA ;
SAVILLE, PD ;
RICHELLE, LJ .
JOURNAL OF CLINICAL INVESTIGATION, 1963, 42 (06) :898-&
[10]
BRONNER F, 1973, CALCIUM PHOSPHORUS M, P149